Tebentafusp (Kimmtrak)
Jump to navigation
Jump to search
Mechanism of action
Bispecific protein consisting of an affinity-enhanced T-cell receptor fused to an anti-CD3 effector that can redirect T cells to target glycoprotein 100-positive cells.
Diseases for which it is used
History of changes in FDA indication
- 1/25/2022: Approved for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma. (Based on IMCgp100-202)
Also known as
- Code name: IMCgp100
- Generic name: tebentafusp-tebn
- Brand name: Kimmtrak